Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL659465 | 0.98 | CHRM2 (0.43) | CHRM2CHRM1LMNAHTTKMT2A | |
| SCHEMBL28473950 | 0.84 | CHRM2 (0.45) | CHRM2CHRM1LMNAHTTKMT2A | |
| SCHEMBL131930 | 0.84 | — | — | |
| Water SCHEMBL955956 | 0.82 | — | — | |
| Water SCHEMBL421187 | 0.82 | — | — | |
| SCHEMBL64211 | 0.81 | CHRM2 (0.47) | CHRM2CHRM1LMNAHTTKMT2A | |
| SCHEMBL3178617 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1LMNAHTTKMT2A | |
| SCHEMBL22345800 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1LMNAHTTKMT2A | |
| SCHEMBL27831166 | 0.78 | CHRM2 (0.45) | CHRM2CHRM1LMNAHTTKMT2A | |
| SCHEMBL5062392 | 0.77 | CHRM2 (0.40) | CHRM2CHRM1LMNAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1690 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | VANELTIX PHARMA, INC. (US) | 2025-12-09 | — | — | US | claimed |
| US-20250312297-A1 | REDUCTION OF HEALTHCARE RESOURCE UTILIZATION BY PATIENTS TREATED WITH INTRANASALLY-ADMINISTERED METOCLOPRAMIDE | EVOKE PHARMA, INC. | 2025-10-09 | — | — | US | claimed |
| US-20250302777-A1 | METHODS FOR TREATING GASTROPARESIS | EVOKE PHARMA, INC. | 2025-10-02 | — | — | US | claimed |
| US-20250228803-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | EVOKE PHARMA, INC. | 2025-07-17 | — | — | US | claimed |
| EP-3494396-B1 | CHEMILUMINESCENT AND FLUORESCENT SUBSTRATE PADS AND USES THEREOF | PIERCE BIOTECHNOLOGY INC (US) | 2025-06-11 | — | — | EP | claimed |
| US-12194008-B2 | Nasal formulations of metoclopramide | EVOKE PHARMA, INC. (US) | 2025-01-14 | — | — | US | claimed |
| US-12194009-B2 | Nasal formulations of metoclopramide | EVOKE PHARMA, INC. (US) | 2025-01-14 | — | — | US | claimed |
| CN-118006725-A | Creatinine detection kit and method | 北京利德曼生化股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| EP-3280444-B1 | METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES | ADIMAB LLC (US) | 2024-05-08 | — | — | EP | claimed |
| CN-112313727-B | Method and package for preparing buffer solution and kit for clinical test | 瑞乐文特生物有限公司 | 2023-12-22 | — | — | CN | claimed |
| US-20020182600-A1 | Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques | SMITH JACK V (US) | 2002-12-05 | — | — | US | claimed |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | MYLAN PHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | claimed |
| WO-2002083113-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL AND A STEROID SUCH AS E.G. BUDESONIDE OR FLUTICASONE FOR DELIVERY INTO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | claimed |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | MYLAN TECHNOLOGIES, INC. | 2002-10-17 | — | — | US | claimed |
| US-20020151597-A1 | Formoterol, or a derivative; long term storage stability | DEY L.P. | 2002-10-17 | — | — | US | claimed |
| US-6176913-B1 | CONTAINING ANIONIC DYE AND BUFFER | HEWLETT PACKARD COMPANY | 2001-01-23 | — | — | US | claimed |
| EP-0997504-A1 | Inks for ink-jet printers | Hewlett-Packard Company (US) | 2000-05-03 | — | — | EP | claimed |
| US-5563644-A | Ink jet printing processes with microwave drying | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| EP-0559324-B1 | Ink jet printing processes with microwave drying | XEROX CORP (US) | 1995-10-18 | — | — | EP | claimed |
| US-5354442-A | Matrix modification in the electrophoretic separation of nucleic acids | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE COMMERCE (US) | 1994-10-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | OGFR, ALOX5, PTGS1 | CHRM2 2397/4885CHRM1 2318/4885LMNA 4660/4885 |
| US-20020151597-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | CHRM2 23/4885CHRM1 46/4885LMNA 908/4885 |
| US-12194008-B2 | Nasal formulations of metoclopramide | MC2R, MTNR1B, MC4R | CHRM2 659/4885CHRM1 1282/4885LMNA 2480/4885 |
| US-20250228803-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | MC2R, MTNR1B, MC4R | CHRM2 659/4885CHRM1 1282/4885LMNA 2480/4885 |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | AREG, IL5, IL17A | CHRM2 202/4885CHRM1 344/4885LMNA 1095/4885 |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | CHRM2 23/4885CHRM1 46/4885LMNA 908/4885 |
| US-12194009-B2 | Nasal formulations of metoclopramide | MC2R, MTNR1B, MC4R | CHRM2 659/4885CHRM1 1282/4885LMNA 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.